Listar por autor "Martínez-García, M."
Mostrando ítems 1-2 de 2
-
Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER1) node-negative breast cancer
Albanell, J.; González, A.; Ruiz-Borrego, M; Alba-Conejo, Emilio
; García-Saenz, J.A.; Corominas, J. M.; Burgues, O.; Furio, V.; Rojo, A.; Palacios, J.; Bermejo, B.; Martínez-García, M.; Limón, L.M.; Sánchez-Muñoz, Alfonso; Martín, M.; Tusquets, I.; Rojo, R.; Colomer, R.; Faull, F.; Lluch, A.[et al.] (Elsevier, 2012-03)
This study examined the impact of the Recurrence Score (RS) in Spanish breast cancer patients and explored the associations between clinicopathological markers and likelihood of change in treatment recommendations. Patients ... -
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).
Albanell, J.; Martínez-García, M.; Ramos-Boyero, Manuel; O'Connor, Miriam; De-la-Cruz-Merino, Luis; Santaballa-Bertrán, Ana; Martínez-Jáñez, Noelia; Moreno-Antón, Fernando; Fernández, Isaura; Alarcón, Jesús Damián; Virizuela-Echaburu, Javier Antonio; De-la-Haba-Rodríguez, Juan Rafael; Sánchez- Rovira, P; González-Cortijo, Lucía; Margelí, Mireia; Sánchez-Muñoz, Alfonso; Antón, A.; Casas, María Isabel; Bezares, Susana; Rojo, Federico[et al.] (Elsevier, 2022)
Background: The potential benefit of adding palbociclib to fulvestrant as first-line treatment in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative endocrine-sensitive advanced breast ...